These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 28588015)

  • 1. Intravesical BCG Induces CD4
    Kates M; Nirschl T; Sopko NA; Matsui H; Kochel CM; Reis LO; Netto GJ; Hoque MO; Hahn NM; McConkey DJ; Baras AS; Drake CG; Bivalacqua TJ
    Cancer Immunol Res; 2017 Jul; 5(7):594-603. PubMed ID: 28588015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
    Derré L; Cesson V; Lucca I; Cerantola Y; Valerio M; Fritschi U; Vlamopoulos Y; Burruni R; Legris AS; Dartiguenave F; Gharbi D; Martin V; Vaucher L; Speiser DE; Romero P; Jichlinski P; Nardelli-Haefliger D
    Clin Cancer Res; 2017 Feb; 23(3):717-725. PubMed ID: 27521445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Additive antitumor effect of arsenic trioxide combined with intravesical bacillus Calmette-Guerin immunotherapy against bladder cancer through blockade of the IER3/Nrf2 pathway.
    Mao MH; Huang HB; Zhang XL; Li K; Liu YL; Wang P
    Biomed Pharmacother; 2018 Nov; 107():1093-1103. PubMed ID: 30257321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic versus localized Bacillus Calmette Guérin immunotherapy of bladder cancer promotes an anti-tumoral microenvironment: Novel role of trained immunity.
    Atallah A; Grossman A; Nauman RW; Paré JF; Khan A; Siemens DR; Cotechini T; Graham CH
    Int J Cancer; 2024 Jul; 155(2):352-364. PubMed ID: 38483404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in mucosal immune cells of bladder tumor patient after BCG intravesical immunotherapy.
    Chang SG; Lee SJ; Huh JS; Lee JH
    Oncol Rep; 2001; 8(2):257-61. PubMed ID: 11182036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials.
    Kates M; Matoso A; Choi W; Baras AS; Daniels MJ; Lombardo K; Brant A; Mikkilineni N; McConkey DJ; Kamat AM; Svatek RS; Porten SP; Meeks JJ; Lerner SP; Dinney CP; Black PC; McKiernan JM; Anderson C; Drake CG; Bivalacqua TJ
    Clin Cancer Res; 2020 Feb; 26(4):882-891. PubMed ID: 31712383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical Bacillus Calmette-Guérin therapy in bladder cancer.
    Pichler R; Fritz J; Zavadil C; Schäfer G; Culig Z; Brunner A
    Oncotarget; 2016 Jun; 7(26):39916-39930. PubMed ID: 27221038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunological Hallmarks for Clinical Response to BCG in Bladder Cancer.
    Lim CJ; Nguyen PHD; Wasser M; Kumar P; Lee YH; Nasir NJM; Chua C; Lai L; Hazirah SN; Loh JJH; Khor LY; Yeong J; Lim TKH; Low AWX; Albani S; Chong TW; Chew V
    Front Immunol; 2020; 11():615091. PubMed ID: 33584702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity.
    Mangsbo SM; Ninalga C; Essand M; Loskog A; Tötterman TH
    J Immunother; 2008 Jan; 31(1):34-42. PubMed ID: 18157010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti-PD-L1 Immune Checkpoint Inhibitor.
    Vandeveer AJ; Fallon JK; Tighe R; Sabzevari H; Schlom J; Greiner JW
    Cancer Immunol Res; 2016 May; 4(5):452-62. PubMed ID: 26921031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cationized liposomal keto-mycolic acids isolated from Mycobacterium bovis bacillus Calmette-Guérin induce antitumor immunity in a syngeneic murine bladder cancer model.
    Yoshino T; Miyazaki J; Kojima T; Kandori S; Shiga M; Kawahara T; Kimura T; Naka T; Kiyohara H; Watanabe M; Yamasaki S; Akaza H; Yano I; Nishiyama H
    PLoS One; 2019; 14(1):e0209196. PubMed ID: 30608942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of lymphocytic responses after treatment with Bacillus Calmette-Guerin and interferon-alpha 2b for superficial bladder cancer.
    Gan YH; Mahendran R; James K; Lawrencia C; Esuvaranathan K
    Clin Immunol; 1999 Feb; 90(2):230-7. PubMed ID: 10080835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T-cell subsets required for intravesical BCG immunotherapy for bladder cancer.
    Ratliff TL; Ritchey JK; Yuan JJ; Andriole GL; Catalona WJ
    J Urol; 1993 Sep; 150(3):1018-23. PubMed ID: 8102183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BCG invokes superior STING-mediated innate immune response over radiotherapy in a carcinogen murine model of urothelial cancer.
    Lombardo KA; Obradovic A; Singh AK; Liu JL; Joice G; Kates M; Bishai W; McConkey D; Chaux A; Eich ML; Rezaei MK; Netto GJ; Drake CG; Tran P; Matoso A; Bivalacqua TJ
    J Pathol; 2022 Feb; 256(2):223-234. PubMed ID: 34731491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on the Mechanism of Action of Intravesical BCG Therapy to Treat Non-Muscle-Invasive Bladder Cancer.
    Abou Chakra M; Luo Y; Duquesne I; A O'Donnell M
    Front Biosci (Landmark Ed); 2024 Aug; 29(8):295. PubMed ID: 39206898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baseline Cytokine Profiles of Tuberculin-Specific CD4
    Jallad S; Thomas P; Newport MJ; Kern F
    Cancer Immunol Res; 2018 Oct; 6(10):1212-1219. PubMed ID: 30120103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravesical Immunomodulatory Imiquimod Enhances Bacillus Calmette-Guérin Downregulation of Nonmuscle-invasive Bladder Cancer.
    Camargo JA; Passos GR; Ferrari KL; Billis A; Saad MJA; Reis LO
    Clin Genitourin Cancer; 2018 Jun; 16(3):e587-e593. PubMed ID: 29174504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the immunologic mechanism of intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors: distribution and function of immune cells.
    Chung JY; Lee ES; Lee WJ; Kim HH; Min KJ; Lee C
    J Korean Med Sci; 1993 Apr; 8(2):135-44. PubMed ID: 8397930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bacillus Calmette-Guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy.
    Rentsch CA; Birkhäuser FD; Biot C; Gsponer JR; Bisiaux A; Wetterauer C; Lagranderie M; Marchal G; Orgeur M; Bouchier C; Bachmann A; Ingersoll MA; Brosch R; Albert ML; Thalmann GN
    Eur Urol; 2014 Oct; 66(4):677-88. PubMed ID: 24674149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of intravesical therapy with platelet-rich plasma (PRP) and Bacillus Calmette-Guérin (BCG) in non-muscle invasive bladder cancer.
    Dias LP; Luzo ÂCM; Volpe BB; Durán M; Galdames SEM; Ferreira LAB; Durán N; Fávaro WJ
    Tissue Cell; 2018 Jun; 52():17-27. PubMed ID: 29857824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.